NCT06963346View on ClinicalTrials.gov

Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 24, 2025

Primary Completion Date

April 30, 2028

Study Completion Date

April 30, 2028

Conditions
Bladder Cancer
Interventions
DRUG

Romidepsin

Administered as intravesical treatment.

DRUG

Durvalumab

Administered as intravenous treatment.

Trial Locations (1)

33612

RECRUITING

Moffitt Cancer Center, Tampa

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER